期刊
CURRENT OPINION IN LIPIDOLOGY
卷 20, 期 6, 页码 467-476出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOL.0b013e3283325083
关键词
cholesterol; extended-release niacin; high-density lipoprotein; laropiprant; low-density lipoprotein; niacin; nicotinic acid; triglycerides
资金
- Merck
Purpose of review Niacin is a B-complex vitamin used as a lipid-altering drug since the 1950s. Niacin improves multiple lipid parameters. Atherosclerotic coronary heart disease outcome studies support niacin's efficacy in reducing coronary heart disease events, either as monotherapy or when used in combination with other lipid-altering drugs. The most commonly reported reason for the lack of its more widespread clinical use is niacin-induced flushing. Recent findings Laropiprant is a highly selective prostaglandin D2 receptor 1 antagonist that mitigates niacin-incluced flushing. Summary This review examines the history and provides a perspective regarding the extended-release niacin/laropiprant development program, which was designed to better allow patients to achieve a more therapeutic niacin dose of 2 g/day, without the need for titration. Ongoing coronary heart disease outcome studies will provide better insight as to the benefits of niacin in general, and the safety and efficacy of extended-release niacin/laropiprant specifically.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据